Actuate Therapeutics, Inc Common stock

Yahoo Finance • 20 days ago

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through key anticipated reg... Full story

Yahoo Finance • last month

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of hig... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index falling 0.8% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of hig... Full story

Yahoo Finance • last month

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of hig... Full story

Yahoo Finance • 2 months ago

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the... Full story

Yahoo Finance • 3 months ago

Actuate Therapeutics stock maintains Buy rating at H.C. Wainwright

Investing.com - H.C. Wainwright reiterated its Buy rating and $20.00 price target on Actuate Therapeutics (NASDAQ:ACTU), currently trading at $5.76, following the company’s completion of the Phase 1 portion of its ongoing Phase 1/2 trial... Full story

Yahoo Finance • 3 months ago

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two Additional Patients Had Durable Stable Disease in... Full story

Yahoo Finance • 3 months ago

Bios 2024 co-invest buys ACTU stock worth $499,996

On June 27, 2025, Bios 2024 Co-Invest, LP, a director and 10% owner of Actuate Therapeutics , Inc. (NASDAQ:ACTU), purchased 71,428 shares of common stock at $7.0, for a total value of $499,996. The purchase comes as the stock has declined... Full story

Yahoo Finance • 3 months ago

Actuate therapeutics director Kreis buys $499,996 in shares

Director Leslie W. Kreis, along with entities he is affiliated with, reported purchasing 71,428 shares of Actuate Therapeutics , Inc. (NASDAQ:ACTU) common stock at a price of $7.0 per share, for a total transaction value of $499,996. The... Full story

Yahoo Finance • 4 months ago

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (... Full story

Yahoo Finance • 4 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high... Full story

Yahoo Finance • 4 months ago

Actuate Therapeutics to be included in Russell 3000, Russell 2000 indexes

* Actuate Therapeutics (NASDAQ:ACTU [https://seekingalpha.com/symbol/ACTU]) will be added to the Russell 3000 Index, with automatic inclusion in the Russell 2000 Index, effective after the U.S. market close on June 27, as part of the 202... Full story

Yahoo Finance • 4 months ago

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Inclusion reflects continued growth and momentum in the company’s mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therape... Full story

Yahoo Finance • 4 months ago

Actuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancer

[Pancreatitis, pancreatic cancer, Asian doctor with pancreas, gallbladder and bile duct human anatomy model at hospital.] sasirin pamai/iStock via Getty Images Actuate Therapeutics (NASDAQ:ACTU [https://seekingalpha.com/symbol/ACTU]) on S... Full story

Yahoo Finance • 4 months ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreat... Full story

Yahoo Finance • 5 months ago

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)Oral presentation at the American Society of Clinical... Full story

Yahoo Finance • 6 months ago

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusibin combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas,... Full story

Yahoo Finance • 6 months ago

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of hi... Full story

Yahoo Finance • 8 months ago

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high... Full story